Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

VSTM

+ Watchlist+ Portfolio

Verastem, Inc.

Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$7.41
52-Week Range
$3.43 – $10.82
Market Cap
$865.72M
P/E (TTM)
—
EPS (TTM)
-1.84
Dividend Yield
0.00%
Advanced Metrics
Price/Book
64.21
PEG Ratio
—
Return on Equity
—
Return on Assets
-59.75%
Gross Margin
87.23%
Operating Margin
-193.73%
Profit Margin
-178.38%
Current Ratio
1.93
Debt/Equity
12.73
Total Debt
$128.56M
Free Cash Flow
$-92.65M
Revenue Growth
113.60%
Earnings Growth
—
Enterprise Value
$821.48M

Market Snapshot

About

Verastem, Inc. is a biopharmaceutical company committed to developing and commercializing medicines to improve the lives of patients diagnosed with cancer. The company focuses on treatments targeting critical signaling pathways in cancer cells, with a particular emphasis on therapies for RAS pathway-driven cancers and difficult-to-treat malignancies. Verastem employs precision medicine approaches to identify patients most likely to benefit from its targeted therapies.